To investigate whether the c-Src/Smad1 pathway plays a pivotal role in developing glomerulosclerosis, we administered a Src specific inhibitor, PP2, to Thy1 GN rats from days 0 to 6 and assessed glomerulosclerosis on day 6. Here, SRC is linked to glomerulosclerosis.